Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $40,863 - $51,704
-269 Reduced 80.54%
65 $10,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $45,119 - $51,847
269 Added 413.85%
334 $63,000
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $9,854 - $11,513
65 New
65 $10,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.